ERRATUM

Denosumab for bone diseases: translating bone biology into targeted therapy

Elena Tsourdi^{1,*}, Tilman D Rachner^{1,*}, Martina Rauner¹, Christine Hamann² and Lorenz C Hofbauer^{1,3}

¹Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technical University Medical Center, Fetscherstrasse 74, D-01307 Dresden, Germany, ²Department of Orthopedics, Technical University Medical Center, D-01307 Dresden, Germany and ³Center for Regenerative Therapies Dresden, D-01307 Dresden, Germany

(Correspondence should be addressed to L C Hofbauer at Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III, Technical University Medical Center; Email: lorenz.hofbauer@uniklinikum-dresden.de)

*(E Tsourdi and T D Rachner contributed equally to this work)

The authors and the journal apologise for an error in this article published in the *European Journal of Endocrinology* 2011 Vol **165** pp 833–840. In table 2, the direction of the first arrow in the column titled Fx/SRE should be pointing downwards and not as published. The correct table is published in full below.

European Journal of Endocrinology **166** 137

Table 2 Denosumab studies.

Name	Phase	n	Results			References
			BTM	BMD	Fx/SRE	
Single-dose placebo-controlled in postmenopausal women	1	49	↓	NA	NA	(24)
Efficacy and safety in postmenopausal women with low BMD	2	412	↓	↑	NA	(33)
Treatment of postmenopausal osteoporosis (FREEDOM)	3	7868	↓	↑	↓	(37)
Prevention of postmenopausal osteoporosis	3	332	↓	↑	NA	(35)
Comparison with alendronate in postmenopausal women with low BMD (DECIDE)	3	1189	↓	↑	NA	(39)
Treatment of bone loss in men on androgen deprivation treatment for non-metastatic prostate cancer (HALT)	3	1468	NA	↑	↓	(41)
Treatment of bone loss in women on aromatase inhibitors for non-metastatic breast cancer	3	252	NA	↑	NA	(40)
Denosumab versus zoledronic acid for the treatment of bone metastases in advanced breast cancer	3	2046	↓	NA	↓	(42)
Denosumab versus zoledronic acid for the treatment of bone metastases in castration-resistant prostate cancer	3	1904	↓	NA	↓	(43)

BMD, bone mineral density; BTM, bone turnover marker; Fx, fracture; NA, not available; SRE, skeletal-related event.